UNRAVELING THE IMPACT OF THE FECAL MICROBIAL TRANSPLANT IN COLO-RECTAL CANCER: INSIGHTS INTO TREATMENT AS AN ADJUVANT - A LITERATURE REVIEW

Background and Objective: Fecal Microbial Transplantation (FMT) can be used as an adjuvant therapy for colorectal cancer (CRC) treatment. The current literature review aimed to determine the effectiveness of FMT in improving treatment outcomes in CRC patients, particularly in conjunction with conventional therapies such as chemotherapy, Radiation and immunotherapy. The underlying mechanisms by which FMT influences immune modulation and gut microbiota composition, thereby impacting CRC progression and treatment outcomes is also discussed. After examining the data, FMT as an adjuvant with conventional therapies has better outcomes in colorectal cancer patients.

Methodology: Using online search engines and databases like PubMed and Google scholar that were published between 2009 and 2024, the most relevant published research, including original papers, was assessed, and critically examined throughout the course of a scientific literature search. This article offers valuable insights into the various treatment options of colorectal cancer and implication of FMT as an adjuvant.

Results: Clinical trials showed that combining FMT with chemotherapy improved treatment effectiveness in colorectal cancer. FMT was well-tolerated and enhanced chemotherapys effects. Another study highlighted FMTs potential in influencing gut microbiota, important in cancer development and treatment response. These findings suggest a growing interest in using FMT alongside other therapies for colorectal cancer.

Conclusion: In comparison to treatment with traditional strategies alone, Fecal microbial transplantation, along with chemotherapy, immunotherapy or radiation, improves the prognosis of colon cancer treatment.